BR112018005407A8 - Anticorpos que especificamente se ligam a tl1a. - Google Patents

Anticorpos que especificamente se ligam a tl1a.

Info

Publication number
BR112018005407A8
BR112018005407A8 BR112018005407A BR112018005407A BR112018005407A8 BR 112018005407 A8 BR112018005407 A8 BR 112018005407A8 BR 112018005407 A BR112018005407 A BR 112018005407A BR 112018005407 A BR112018005407 A BR 112018005407A BR 112018005407 A8 BR112018005407 A8 BR 112018005407A8
Authority
BR
Brazil
Prior art keywords
antibodies
tl1a
disease
cystic fibrosis
specifically bind
Prior art date
Application number
BR112018005407A
Other languages
English (en)
Other versions
BR112018005407A2 (pt
Inventor
Dorothy Poulton Lynn
Pollard Matthew
G Doyle Anthony
Ann Cooksey Bridget
Pande Vanya
William Clarke Adam
Original Assignee
Cephalon Inc
Cephalon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Cephalon Llc filed Critical Cephalon Inc
Publication of BR112018005407A2 publication Critical patent/BR112018005407A2/pt
Publication of BR112018005407A8 publication Critical patent/BR112018005407A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS QUE ESPECIFICAMENTE SE LIGAM A TLIA. Os anticorpos variantes expressos de forma recombinante que têm afinidade aumentada para TL1A e potência aumentada em relação ao anticorpo progenitor a partir do qual foram derivados são fornecidos. Os anticorpos inibem a interação entre TL1A e o receptor de morte 3 (DR3). Os anticorpos, ou uma composição destes, podem ser usados para tratar uma ou mais de asma, COPD, fibrose pulmonar, fibrose cística, doença inflamatória intestinal, doença gastrointestinal associada à fibrose cística, doença de Crohn, colite, colite ulcerosa, síndrome do intestino irritável, esofagite eosinófila, dermatite atópica, eczema, esclerodermia, artrite ou artrite reumatoide.
BR112018005407A 2015-09-18 2016-09-16 Anticorpos que especificamente se ligam a tl1a. BR112018005407A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18
PCT/US2016/052040 WO2017049024A1 (en) 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a

Publications (2)

Publication Number Publication Date
BR112018005407A2 BR112018005407A2 (pt) 2018-10-09
BR112018005407A8 true BR112018005407A8 (pt) 2023-01-24

Family

ID=57043002

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018005407A BR112018005407A8 (pt) 2015-09-18 2016-09-16 Anticorpos que especificamente se ligam a tl1a.
BR122021002400A BR122021002400A8 (pt) 2015-09-18 2016-09-16 Anticorpos que especificamente se ligam a tl1a

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021002400A BR122021002400A8 (pt) 2015-09-18 2016-09-16 Anticorpos que especificamente se ligam a tl1a

Country Status (33)

Country Link
US (3) US10138296B2 (pt)
EP (2) EP3350223B1 (pt)
JP (2) JP7013366B2 (pt)
KR (1) KR101998535B1 (pt)
CN (1) CN108137693B (pt)
AR (1) AR106055A1 (pt)
AU (2) AU2016323460B2 (pt)
BR (2) BR112018005407A8 (pt)
CA (1) CA2997015A1 (pt)
CL (1) CL2018000711A1 (pt)
CO (1) CO2018003736A2 (pt)
CY (1) CY1123499T1 (pt)
DK (1) DK3350223T3 (pt)
EA (1) EA201890756A1 (pt)
ES (1) ES2810751T3 (pt)
HK (2) HK1251002A1 (pt)
HR (1) HRP20201323T1 (pt)
HU (1) HUE051496T2 (pt)
IL (1) IL257761B2 (pt)
LT (1) LT3350223T (pt)
MA (2) MA52643A (pt)
MD (1) MD3350223T2 (pt)
MX (1) MX2018003185A (pt)
PE (1) PE20181080A1 (pt)
PH (1) PH12018500580A1 (pt)
PL (1) PL3350223T3 (pt)
PT (1) PT3350223T (pt)
RS (1) RS60703B1 (pt)
SI (1) SI3350223T1 (pt)
TW (1) TWI703158B (pt)
UA (1) UA125284C2 (pt)
WO (1) WO2017049024A1 (pt)
ZA (1) ZA201801427B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
BR122020013379B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
EP2978440B1 (en) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
AU2016364992B2 (en) * 2015-12-04 2021-12-09 University Of Iowa Research Foundation Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
US10322174B2 (en) 2016-10-26 2019-06-18 Cedars-Sinai Medical Center Neutralizing anti-TL1A monoclonal antibodies
EP3784699A4 (en) 2018-04-25 2022-04-13 Prometheus Biosciences, Inc. OPTIMIZED ANTI-TL1A ANTIBODIES
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
WO2024026386A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations
WO2024026395A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
CN1237076C (zh) 1999-01-15 2006-01-18 杰南技术公司 具有改变的效应功能的多肽变体
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
DK1919954T3 (en) 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
WO2007076465A2 (en) 2005-12-23 2007-07-05 Diadexus, Inc. Cln248 antibody compositions and methods of use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106451A2 (en) 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
CA2705292C (en) 2007-11-13 2016-06-21 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against tl1a
WO2010118210A1 (en) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
WO2011080314A2 (en) 2009-12-31 2011-07-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
MX2013013329A (es) 2011-05-20 2014-04-16 Us Government Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
BR122020013379B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
AP2015008605A0 (en) * 2013-01-02 2015-07-31 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses
EP2978440B1 (en) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
CN105307676A (zh) * 2013-04-05 2016-02-03 豪夫迈·罗氏有限公司 抗il-4抗体和双特异性抗体及其用途
US20160096885A1 (en) 2013-05-17 2016-04-07 Cedars-Sinal Medical Center Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
EP3041580A4 (en) 2013-09-06 2017-05-03 Cedars-Sinai Medical Center Systems, devices and methods for anti-tl1a therapy
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
PT3283499T (pt) 2015-04-15 2022-08-23 Biosearch Tech Inc Sondas de extintor dual
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS

Also Published As

Publication number Publication date
US20170081400A1 (en) 2017-03-23
PE20181080A1 (es) 2018-07-05
CY1123499T1 (el) 2022-03-24
ES2810751T3 (es) 2021-03-09
HK1251002A1 (zh) 2019-01-18
TWI703158B (zh) 2020-09-01
ZA201801427B (en) 2019-06-26
EP3693393A1 (en) 2020-08-12
PT3350223T (pt) 2020-08-05
EP3350223B1 (en) 2020-06-17
IL257761A (en) 2018-04-30
JP2018528773A (ja) 2018-10-04
BR122021002400A2 (pt) 2018-10-09
MA52643A (fr) 2021-03-24
EA201890756A1 (ru) 2018-08-31
AU2023203440A1 (en) 2023-06-29
CA2997015A1 (en) 2017-03-23
IL257761B2 (en) 2023-03-01
SI3350223T1 (sl) 2020-10-30
JP2022051771A (ja) 2022-04-01
US20220185902A1 (en) 2022-06-16
TW201722990A (zh) 2017-07-01
BR122021002400A8 (pt) 2023-01-24
IL257761B (en) 2022-11-01
CO2018003736A2 (es) 2018-07-10
US20190106486A1 (en) 2019-04-11
EP3350223A1 (en) 2018-07-25
BR112018005407A2 (pt) 2018-10-09
AR106055A1 (es) 2017-12-06
CN108137693A (zh) 2018-06-08
MD3350223T2 (ro) 2020-09-30
AU2016323460A1 (en) 2018-03-29
AU2016323460B2 (en) 2023-06-15
RS60703B1 (sr) 2020-09-30
KR20180048712A (ko) 2018-05-10
MA42825B1 (fr) 2020-09-30
KR101998535B1 (ko) 2019-07-09
PH12018500580A1 (en) 2018-10-15
LT3350223T (lt) 2020-10-26
CL2018000711A1 (es) 2018-11-23
DK3350223T3 (da) 2020-08-24
MX2018003185A (es) 2018-08-01
WO2017049024A1 (en) 2017-03-23
PL3350223T3 (pl) 2021-03-08
JP7013366B2 (ja) 2022-02-15
CN108137693B (zh) 2021-11-26
JP7341259B2 (ja) 2023-09-08
UA125284C2 (uk) 2022-02-16
HUE051496T2 (hu) 2021-03-01
US11220549B2 (en) 2022-01-11
US10138296B2 (en) 2018-11-27
HK1256300A1 (zh) 2019-09-20
HRP20201323T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
BR112018005407A8 (pt) Anticorpos que especificamente se ligam a tl1a.
BR112016026299A2 (pt) molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
AR106801A1 (es) Composiciones que comprenden cepas bacterianas
BR112018001530A2 (pt) anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica
BR112017005692A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112015022260A2 (pt) anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico
BR112017007202A2 (pt) receptores de célula t
BR112017012944A2 (pt) ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza?
BR112019012570A8 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
WO2016207717A8 (en) Anti-vista antibodies and fragments
JP2014099920A5 (pt)
WO2015106080A3 (en) Antibodies directed against interleukin-33 (il-33)
BR112013032871A2 (pt) cepa hospedeira bacteriana que expressa dsbc recombinante
EP4282974A3 (en) Linked duplex target capture
WO2011109726A3 (en) Homologous multi-specific antibodies
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
BR112018003267A2 (pt) chapa de aço
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
BR112019005392A2 (pt) composições de hemicelulose aglomerada, métodos de preparação das mesmas e processos para enriquecer um mineral desejado a partir de um minério
BR112019000788A2 (pt) anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica
BR112017009676A2 (pt) composições de ligante e processos de preparo de peletes de minério de ferro
WO2015170187A3 (en) Improved enrichment methods
Wang et al. Seismic capacity of brick masonry walls externally bonded GFRP under in-plane loading
MX2018005135A (es) Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CEPHALON LLC (US)

B25G Requested change of headquarter approved

Owner name: CEPHALON LLC (US)